Nature: Innovators target vaccines for variants

GreenLight Biosciences is mentioned in Nature Biotechnology for its work on vaccines for variants.

GreenLight Biosciences is mentioned in Nature Biotechnology for its work on vaccines for variants and shortages in the global South. An extract is below:

Even before the pandemic arrived, Tübingen, Germany-based CureVac and CEPI were co-developing portable mRNA printing technology, which could rapidly produce hundreds of thousands of vaccine doses in localized settings. “We have a ‘wave 2’ portfolio that we put in place last year,” says Jackson. This remains at the prototype stage, Jackson says.

“It really is the ticket for mRNA having a global impact in the future.” CEPI is also “in active discussions” with GreenLight Biosciences, which has developed a low-cost cell-free mRNA production method that relies on harvesting nucleotides from yeast biomass.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.